Search | Page 6 | Aplastic Anemia and MDS International Foundation


Search results

  1. Pathogenesis of MDS: An overview of molecular and non-molecular aspects of the disease

    ... PubMed Abstract:  Pathogenesis of MDS: An Overview of molecular and non-molecular aspects of the disease ... are found in approximately 50% of primary MDS and 80% of secondary MDS , which develops in the setting of prior chemotherapy ...

    Research Review last updated 05/02/2016 - 9:14am.

  2. Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide

    ... myelodysplastic syndromes (MDS) Associated Drug(s):  ... AML arising from MDS or a myeloproliferative disorder, or secondary AML Presence of Flt3 internal tandem duplications Poor-risk ...

    Clinical Trial last updated 05/02/2016 - 2:38pm.

  3. Bone Marrow Transplant

    ... doctor about bone marrow transplant options. MDS : Whether patients with MDS should undergo hematopoietic stem cell transplantation (HSCT) as soon as ... can also affect SCT outcomes. People with secondary MDS , caused by a previous treatment for another disease or ...

    Topic section last updated 03/29/2016 - 7:27pm.

  4. Youmna Kfoury, PhD

    ... Myelodysplastic Syndromes (MDS) are a group of diverse and incurable pre-leukemic disorders. Even though a ... Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature 464, 852-857. Sacchetti, B., Funari, A., ...

    Grant Recipient last updated 12/15/2016 - 12:56pm.

  5. David Araten, MD

    ... Secondary mutations and thrombosis in PNH ... with the generous support of the Aplastic Anemia and MDS International Foundation, to test a larger number of patients for mutations ...

    Grant Recipient last updated 11/30/2016 - 10:51am.

  6. Hematopoietic Stem Cell Transplantation in Aplastic Anemia

    ... risk of developing myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML).  Many patients treated with ... Also, remember that if aplastic anemia develops into MDS or AML, then outcomes aren’t as good. The survival is lower due to ... What is not known is if eltrombopag affects the risk of secondary events such as relapse and clonal progression, especially in the ...

    Interview last updated 11/28/2016 - 2:58pm.

  7. Bone Marrow and Stem Cell Transplantation

    ... marrow failure disease like aplastic anemia , MDS or PNH , and your doctor thinks you may be a candidate for a ... , can also affect HSCT outcomes. People with secondary MDS , caused by a previous treatment for another disease or ...

    Page last updated 09/30/2014 - 11:47am.

  8. Phase I/II MEK162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard Therapy

    ... to patients with relapsed and/or refractory AML, MDS, or ALL. Status:  ... PHASE I -- a. Primary or secondary AML according to WHO classification, with relapsed or refractory ...

    Clinical Trial last updated 06/06/2016 - 10:59am.

  9. Transplantation


    Page last updated 01/20/2015 - 4:45pm.

  10. Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

    ... myelodysplastic syndromes (MDS) Associated Drug(s):  ... CD123+ acute myeloid leukemia (AML) de novo , or secondary Relapsed AML is defined as patients that had a first ...

    Clinical Trial last updated 07/14/2016 - 4:08pm.